MAPK/ERK


The mitogen-activated protein kinase (MAPK) is a highly conserved family of serine/threonine kinases that mediate a board range of cellular processes, including proliferation, differentiation, motility, migration, stress response, apoptosis and survival. The activation of MAPK involves signaling pathways consisting of MAPK kinase (i.e. MAPKKK or MEKK) that activates MAPK/ERK (i.e. MAPKK or MEK). A variety of extracellular signals such as mitogens, cytokines, growth factors, and environmental stressors stimulate a phosphorylation-dependent increase in the activity of MAPK.
Activated MAPKs transduce the phosphorylation and activation of MAPK-activated protein kinases (MAPKAPKs), e.g. RSK, MSK, or MNK family, and MK2/3/5. There are three main MAPK families, signal-regulated kinase 1 and 2 (Erk1/2 or p44/42), the c-Jun N-terminal kinases 1-3 (JNK1-3)/ stress activated protein kinases (SAPK1A, 1B, 1C), the p38 isoforms (p38α, β, γ, and δ). ERK signaling is involved in cell division, migration and survival. p38 MAPK and JNK/SAPK pathways are activated by cellular stress. The p38 MAPK pathway regulates cell motility, transcription, and chromatin remodeling. JNK/SAPK signaling affects apoptosis and inflammation. Dysregulation of MAPK pathway results in tumorgenesis and other pathological conditions.
-
BA5773 KRA-533Summary: KRA-533 is a potent agonist. -
BA6105 MSU-42011Summary: MSU-42011 is an orally active retinoid X receptor agonist. -
BA6439 BIX02188Summary: BIX02188 is a potent and selective inhibitor. -
BA6445 α-AmyrinSummary: α-Amyrin is a pentacyclic triterpenoid with oral activity. -
BA6455 HirsutenoneSummary: Hirsutenone, an active diheptanone contained in alder, has a variety of biological activities including anti-inflammatory, anti-tumor and anti-atopic dermatitis. -
BA6471 SR15006Summary: Kruppel-likefactor5 (KLF5) inhibitor agent. -
BA6475 DLK-IN-1Summary: DLK-IN-1 is a selective inhibitor of double leucine zipper kinase with oral activity. -
BA6476 GNE-8505Summary: An orally effective inhibitor. -
BA6501 NedometinibSummary: Nedometinib is a tyrosine kinase inhibitor that is targeted. -
BA6511 VNPP433-3βSummary: VNPP433-3β is a molecular gel degrader that targets androgen receptor and its splice variants and serine/threonine protein kinases that interact with MAP kinase.

